查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
外阴道念珠菌病药物市场按药物类型（克霉唑、氟康唑、特康唑）、给药途径、分销渠道和地区规模、份额和趋势分析（2022-2030）
市场调查报告书
商品编码
1170942

外阴道念珠菌病药物市场按药物类型（克霉唑、氟康唑、特康唑）、给药途径、分销渠道和地区规模、份额和趋势分析（2022-2030）

Vulvovaginal Candidiasis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Clotrimazole, Fluconazole, Terconazole), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

2022年至2030年，全球外阴阴道念珠菌病药物市场预计将以4.39%的复合年增长率增长，2030年将达到16.4亿美元。

外阴阴道念珠菌病的疾病负担不断增加、批准能够解决未满足需求的新药以及政府和非营利组织为提高认识所做的努力等因素正在推动行业发展。

到 2021 年，由于高处方率和缺乏具有类似疗效的其他药物，氟康唑部分将占据最大份额。 此外，由于非处方药和唑类乳膏和软膏等处方药的存在，预计在预测期内，外用药物细分市场将以稳定的复合年增长率增长。

本报告考察了全球外阴阴道念珠菌病药物市场，并提供了市场概况、对市场增长的各种影响因素的分析、监管和报销框架、管道分析和市场规模趋势。预测，按细分市场/区域/进行的详细分析主要国家、竞争环境、市场份额、主要公司概况等。

内容

第一章调查方法及范围

第 2 章执行摘要

第三章外阴阴道念珠菌病药物市场变数、趋势与展望

  • 描绘扩散和增长前景
  • 用户视角分析
  • 监管和报销框架
  • 市场驱动因素分析
  • 市场製约因素分析
  • COVID-19：影响分析
  • SWOT 分析
  • 行业分析：波特分析
  • 管道分析

第 4 章外阴阴道念珠菌病药物市场：按药物类别分类

  • 趋势分析
  • 克霉唑
  • 制霉菌素
  • 氟康唑
  • 酮康唑
  • 特比□芬
  • 特康唑
  • 其他

第 5 章外阴阴道念珠菌病药物市场：按给药途径

  • 趋势分析
  • 口服剂
  • 静脉注射
  • 外用剂

第 6 章外阴阴道念珠菌病药物市场：按分销渠道

  • 趋势分析
  • 医院药房
  • 零售药房
  • 在线药店

第 7 章外阴阴道念珠菌病药物市场：按地区

  • 定义/范围
  • 市场份额分析
  • 市场概况
  • 市场规模/预测/利润/趋势分析
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第 8 章外阴阴道念珠菌病药物市场：竞争分析

  • 主要进入者的近期发展和影响分析
  • 公司分类
  • 供应商情况
  • 主要公司的市场份额分析
  • 上市公司
  • 私人公司
  • 公司简介
    • ASTELLAS PHARMA INC.
    • MYCOVIA PHARMACEUTICALS, INC.
    • MYCOVIA PHARMACEUTICALS, INC.
    • SCYNEXIS, INC.
    • GRUPO FERRER INTERNACIONAL, SA
    • PFIZER, INC.
    • BAYER AG
    • CADILA PHARMACEUTICALS
    • BRISTOL-MYERS SQUIBB COMPANY
Product Code: GVR-4-68039-997-1

Vulvovaginal Candidiasis Treatment Market Growth & Trends:

The global vulvovaginal candidiasis treatment market size is expected to reach USD 1.64 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.39% from 2022 to 2030. The increasing disease burden of VVC, approval of novel drugs with the ability to address the unmet needs, and efforts by government & non-profit organizations to increase awareness are among the key factors augmenting the industry growth. According to the NCBI article, globally, around 75% of women suffer from this disease once in their life.Vulvovaginal candidiasis is the second most common infection in women, affecting around 138 million women globally.

About 10-20% of women report complicated disease conditions, which are increasing annually. Moreover, the NCBI article reports an upsurge in recurrent infection incidences. Thus, the rising prevalence of the disease is boosting the treatment demand, thereby driving industry growth.Azoles, such as fluconazole, are indicated as the first line of treatment and held a significant share of the market, however, in recent years, there has been a surge in azole resistance cases, which led to rising in recurring disease cases. However, novel drugs, such as VIVJOA and BREXAFEMME, are effectiveagainst recurring VVC. In addition, the presence of over-the-counter intravaginal agents, which enables easy patient treatment access, supports the market growth.

This includes products, such as miconazole cream, clotrimazole cream, and tioconazole ointment. They are indicated to treat mild to moderate conditions and are used as maintenance therapy. The industry is saturated with generic products, which could slow down growth. However, key players, such as Mycovia Pharmaceuticals and SCYNEXIS, Inc., are engaged in strategic initiatives like new product development and launches, which are anticipated to propel the market growth over the forecast period. For instance, in July 2022, Mycovia Pharmaceuticals launched VIVJOA for recurrent VVC. The company has already received VIVJOA approval in Asian, European, and Latin American countries. In September 2021, SCYNEXIS, Inc. launched BREXAFEMME in the U.S., the first oral non-azole therapeutic indicated for VVC.

Vulvovaginal Candidiasis Treatment Market Report Highlights:

  • In 2021, the fluconazole segment accounted for the largest share owing to its high prescription rate and the non-availability of other drugs with similar efficacy
  • The topical segment is estimated to grow at a steady CAGR during the forecast period due to the presence of OTC and prescription formulations, such as azole creams and ointments
  • Based on distribution channel, the retail pharmacy segment dominated the industry in 2021 due to the ease of availability and the presence of OTCs drugs
  • Asia Pacific is anticipated to experience the fastest CAGR over the forecast period due to increased awareness among the population, rise in disposable income, and high prevalence of VVC in developing countries

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Vulvovaginal Candidiasis Treatment market Variables, Trends, and Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 User Perspective Analysis
  • 3.3 Regulatory and Reimbursement Framework
  • 3.4 Market Driver analysis
    • 3.4.1 Rising Prevalence Of The Disease
    • 3.4.2 Strong Emerging Pipeline
  • 3.5 Market Restraint Analysis
    • 3.5.1 Availability Of Generic Drugs In Market
  • 3.6 Covid-19 Impact Analysis
  • 3.7 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.8 Industry Analysis - Porter's
  • 3.9 Pipeline Analysis

Chapter 4 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Vulvovaginal Candidiasis Treatment market: Drug Class Movement Analysis
  • 4.2 Clotrimazole
    • 4.2.1 Clotrimazole Market, 2018 - 2030 (USD Million)
  • 4.3 Nystatin
    • 4.3.1 Nystatin Market, 2018 - 2030 (USD Million)
  • 4.4 Fluconazole
    • 4.4.1 Fluconazole Market, 2018 - 2030 (USD Million)
  • 4.5 Ketoconazole
    • 4.5.1 Ketoconazole Market, 2018 - 2030 (USD Million)
  • 4.6 Terbinafine
    • 4.6.1 Terbinafine Market, 2018 - 2030 (USD Million)
  • 4.7 Terconazole
    • 4.7.1 Terconazole Market, 2018 - 2030 (USD Million)
  • 4.8 Others
    • 4.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 5.1 Vulvovaginal Candidiasis Treatment market: Route of Administration Movement Analysis
  • 5.2 Oral
    • 5.2.1 Oral Market, 2018 - 2030 (USD Million)
  • 5.3 Intravenous
    • 5.3.1 Intravenous Market, 2018 - 2030 (USD Million)
  • 5.4 Topical
    • 5.4.1 Topical Market, 2018 - 2030 (USD Million)

Chapter 6 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1 Vulvovaginal Candidiasis Treatment market: Distribution Channel Movement Analysis
  • 6.2 Hospital Pharmacy
    • 6.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3 Retail Pharmacy
    • 6.3.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4 Online Pharmacy
    • 6.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7 Vulvovaginal Candidiasis Treatment market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Definition & Scope
  • 7.2 Regional Market Share Analysis, 2021 & 2030
  • 7.3 Regional Market Snapshot
  • 7.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
    • 7.4.1 North America
      • 7.4.1.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.1.2 U.S.
      • 7.4.1.2.1 U.S. Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.1.3 Canada
      • 7.4.1.3.1 Canada Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2 Europe
      • 7.4.2.1 Europe Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 U.K.
      • 7.4.2.2.1 U.K. Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.3 Germany
      • 7.4.2.3.1 Germany Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.4 France
      • 7.4.2.4.1 France Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.5 Spain
      • 7.4.2.5.1 Spain Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.6 Italy
      • 7.4.2.6.1 Italy Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3 Asia Pacific
      • 7.4.3.1 Asia Pacific Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Japan
      • 7.4.3.2.1 Japan Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.3 China
      • 7.4.3.3.1 China Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.4 India
      • 7.4.3.4.1 India Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.5 Australia
      • 7.4.3.5.1 Australia Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.6 South Korea
      • 7.4.3.6.1 South Korea Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4 Latin America
      • 7.4.4.1 Latin America Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Brazil
      • 7.4.4.2.1 Brazil Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.3 Mexico
      • 7.4.4.3.1 Mexico Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.4 Argentina
      • 7.4.4.4.1 Argentina Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5 Middle East & Africa
      • 7.4.5.1 Middle East & Africa Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 South Africa
      • 7.4.5.2.1 South Africa Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.3 Saudi Arabia
      • 7.4.5.3.1 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.4 UAE
      • 7.4.5.4.1 UAE Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)

Chapter 8 Vulvovaginal Candidiasis Treatment market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launches
    • 8.1.2 Mergers And Acquisitions
    • 8.1.3 Partnerships And Strategic Collaboration
    • 8.1.4 Conferences And Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
    • 8.2.3 Heat Map Analysis
  • 8.3 Vendor Landscape
    • 8.3.1 List Of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Key Company Market Share Analysis, 2021
  • 8.5 Public Companies
    • 8.5.1 Company Market Position Analysis
    • 8.5.2 Competitive Dashboard Analysis
      • 8.5.2.1 Market Differentiators
  • 8.6 Private Companies
    • 8.6.1 List Of Key Emerging Companies
    • 8.6.2 Regional Network Map
  • 8.7 Company Profiles
    • 8.7.1 ASTELLAS PHARMA INC.
      • 8.7.1.1 Company Overview
      • 8.7.1.2 Financial Performance
      • 8.7.1.3 Product benchmarking
      • 8.7.1.4 Strategic initiatives
    • 8.7.2 MYCOVIA PHARMACEUTICALS, INC.
      • 8.7.2.1 Company overview
      • 8.7.2.2 Financial Performance
      • 8.7.2.3 Product benchmarking
      • 8.7.2.4 Strategic initiatives
    • 8.7.3 MYCOVIA PHARMACEUTICALS, INC.
      • 8.7.3.1 Company Overview
      • 8.7.3.2 Financial Performance
      • 8.7.3.3 Product Benchmarking
      • 8.7.3.4 Strategic Initiatives
    • 8.7.4 SCYNEXIS, INC.
      • 8.7.4.1 Company Overview
      • 8.7.4.2 Financial Performance
      • 8.7.4.3 Product Benchmarking
      • 8.7.4.4 Strategic Initiatives
    • 8.7.5 GRUPO FERRER INTERNACIONAL, S.A.
      • 8.7.5.1 Company Overview
      • 8.7.5.2 Financial Performance
      • 8.7.5.3 Product Benchmarking
      • 8.7.5.4 Strategic Initiatives
    • 8.7.6 PFIZER, INC.
      • 8.7.6.1 Company Overview
      • 8.7.6.2 Financial Performance
      • 8.7.6.3 Product Benchmarking
      • 8.7.6.4 Strategic Initiatives
    • 8.7.7 BAYER AG
      • 8.7.7.1 Company Overview
      • 8.7.7.2 Financial Performance
      • 8.7.7.3 Product Benchmarking
      • 8.7.7.4 Strategic Initiatives
    • 8.7.8 CADILA PHARMACEUTICALS
      • 8.7.8.1 Company Overview
      • 8.7.8.2 Financial Performance
      • 8.7.8.3 Product Benchmarking
      • 8.7.8.4 Strategic Initiatives
    • 8.7.9 BRISTOL-MYERS SQUIBB COMPANY
      • 8.7.9.1 Company overview
      • 8.7.9.2 Financial Performance
      • 8.7.9.3 Product benchmarking
      • 8.7.9.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 List of key distributors
  • Table 4 List of other companies
  • Table 5 List of key emerging companies/technology disruptors/innovators
  • Table 6 Global Vulvovaginal Candidiasis Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 7 Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8 Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 North America Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 11 North America Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 12 North America Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 North America Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 U.S. Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 U.S. Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 U.S. Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Canada Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Europe Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Europe Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 U.K. Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 25 U.K. Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 U.K. Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Germany Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Germany Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 31 France Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 France Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Spain Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Spain Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Italy Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Italy Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Italy Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Japan Vulvovaginal Candidiasis Treatment Market, By Drug Class Type, 2018 - 2030 (USD Million)
  • Table 44 Japan Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Japan Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 China Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 47 China Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 China Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 India Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 50 India Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 India Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Australia Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Australia Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Australia Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 South Korea Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 South Korea Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 South Korea Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Latin America Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 59 Latin America Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Latin America Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Latin America Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Brazil Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Brazil Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Brazil Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Mexico Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Mexico Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Mexico Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Argentina Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Argentina Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Argentina Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 MEA Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 MEA Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 MEA Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 MEA Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 South Africa Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 76 South Africa Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 77 South Africa Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 UAE Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 82 UAE Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 UAE Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million

List of Figures

  • Fig. 1 Vulvovaginal candidiasis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2021)
  • Fig. 10 Penetration and growth prospect mapping
  • Fig. 11 User perspective analysis
  • Fig. 12 Vulvovaginal candidiasis treatment market driver impact
  • Fig. 11 Prevalence of VVC (in 2021)
  • Fig. 12 Vulvovaginal candidiasis treatment market restraint impact
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Vulvovaginal candidiasis treatment drug class outlook: Key takeaways
  • Fig. 16 Vulvovaginal candidiasis treatment market: Drug class movement analysis
  • Fig. 17 Clotrimazole market, 2018 - 2030 (USD million)
  • Fig. 18 Nystatin market, 2018 - 2030 (USD million)
  • Fig. 19 Fluconazole market, 2018 - 2030 (USD million)
  • Fig. 20 Ketoconazole market, 2018 - 2030 (USD million)
  • Fig. 21 Terbinafine market, 2018 - 2030 (USD million)
  • Fig. 22 Terconazole market, 2018 - 2030 (USD million)
  • Fig. 23 Others market, 2018 - 2030 (USD million)
  • Fig. 24 Vulvovaginal candidiasis treatment market route of administration outlook: Key takeaways
  • Fig. 25 Vulvovaginal candidiasis treatment: Route of administration movement analysis
  • Fig. 26 Oral market, 2018 - 2030 (USD million)
  • Fig. 27 Intravenous market, 2018 - 2030 (USD million)
  • Fig. 28 Topical market, 2018 - 2030 (USD million)
  • Fig. 29 Vulvovaginal candidiasis treatment distribution channel outlook: Key takeaways
  • Fig. 30 Vulvovaginal candidiasis treatment market: Distribution channel movement analysis
  • Fig. 31 Hospital pharmacy market, 2018 - 2030 (USD million)
  • Fig. 32 Retail pharmacy market, 2018 - 2030 (USD million)
  • Fig. 33 Online pharmacy market, 2018 - 2030 (USD million)
  • Fig. 34 Regional outlook, 2021 & 2030
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America
  • Fig. 37 North America vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S.
  • Fig. 39 U.S. vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada
  • Fig. 41 Canada vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 U.K.
  • Fig. 45 U.K. vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 France
  • Fig. 49 France vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy
  • Fig. 53 Italy vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific
  • Fig. 55 Asia Pacific vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan
  • Fig. 57 Japan vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 China
  • Fig. 59 China vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 India
  • Fig. 61 India vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia
  • Fig. 63 Australia vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea
  • Fig. 65 South Korea vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America
  • Fig. 67 Latin America vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil
  • Fig. 69 Brazil vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Mexico
  • Fig. 71 Mexico vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina
  • Fig. 73 Argentina vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Middle East & Africa
  • Fig. 75 Middle East & Africa vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa
  • Fig. 77 South Africa vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia
  • Fig. 79 Saudi Arabia vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE
  • Fig. 81 UAE vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Heat map analysis
  • Fig. 83 Company market share analysis (2021)
  • Fig. 84 Company market position analysis (2021)
  • Fig. 85 Company market position analysis (2021)
  • Fig. 86 Market differentiators
  • Fig. 87 Regional Network Map